# Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

> **NCT00021723** · PHASE2 · TERMINATED · sponsor: **JANSSEN Alzheimer Immunotherapy Research & Development, LLC** · enrollment: 375 (—)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** AN-1792 also known as AIP-001

## Key facts

- **NCT ID:** NCT00021723
- **Lead sponsor:** JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-09
- **Primary completion:** —
- **Final completion:** 2003-09
- **Target enrollment:** 375 (—)
- **Last updated:** 2009-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021723, "Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00021723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*